Roche partner touts early allogeneic CAR-T data at #ASH23, but durability remains key question
SAN DIEGO — Poseida Therapeutics revealed the most complete data so far for the allogeneic CAR-T program that it licensed to Roche last year. But it’s likely to face the question that’s dogged this field for years: Can its responses remain durable?
On Sunday the startup presented efficacy data with at least four weeks of follow-up for its therapy P-BCMA-ALLO1, data that were “highly dependent” on a particular part of patients’ preconditioning regimens, according to a press release. Patients who took lower levels of cyclophosphamide — an immunosuppressive and chemotherapy drug — before receiving P-BCMA-ALLO1 infusions did not respond to the CAR-T. Most of those who got higher doses did respond.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.